Comparison · NCT02940860-sae
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: serious adverse events. Trial comparisons, record NCT02940860-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02940860-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0815 | 0.0662 | 0.0999 | wilson | |
| Risk in group 2 | 0.0988 | 0.0758 | 0.128 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0174 | -0.0502 | 0.0121 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.824 | 0.59 | 1.15 | log | |
| Odds ratio, group 1 over group 2 | 0.809 | 0.56 | 1.17 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Iron Isomaltoside/Ferric Derisomaltose than on Iron Sucrose | 57.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | 83 | 1,019 | EG000 |
| Group 2 | Iron Sucrose | Iron sucrose, administered IV | 50 | 506 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
From the time a subjects had signed the informed consent form (CRF) and until they had completed the study, all adverse events (AEs) or serious adverse events (SAEs) were reported in the CRF. The actual study duration was 8 weeks (or shorted if the trial was discontinued). Overall, eligible subjects participated in the trial for approximately 10 weeks (including a 14-day screening period).
Source ClinicalTrials.gov
Trial
- Title
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
- NCT number
- NCT02940860
- Phases
- PHASE3
- Conditions
- Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
- Interventions
- Iron isomaltoside/ferric derisomaltose, Iron sucrose
- Lead sponsor
- Pharmacosmos A/S
- Results first posted
- 2020-03-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02940860?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02940860-sae